GAO Ballot Package

This page is part of the FHIR Specification (v1.1.0: STU 3 Ballot 1). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions

This is a frozen snapshot of the FHIR specification created for the purpose of balloting the GAO implementation Guide. It includes draft changes that may be part of the future DSTU 2.1 release but further change is expected. Readers should focus solely on the GAO implementation content, and FHIR DSTU 2 for other purposes.

V2-0477.json

Raw JSON (canonical form)

FHIR Value set/code system definition for HL7 v2 table 0477 ( Controlled Substance Schedule)

{
  "resourceType": "ValueSet",
  "id": "v2-0477",
  "meta": {
    "profile": [
      "http://hl7.org/fhir/StructureDefinition/valueset-shareable-definition"
    ]
  },
  "text": {
    "status": "additional",
    "div": "<div>!-- Snipped for Brevity --></div>"
  },
  "url": "http://hl7.org/fhir/ValueSet/v2-0477",
  "version": "2.8.2",
  "name": "v2 Controlled Substance Schedule",
  "status": "active",
  "experimental": true,
  "publisher": "HL7, Inc",
  "contact": [
    {
      "telecom": [
        {
          "system": "other",
          "value": "http://hl7.org"
        }
      ]
    }
  ],
  "description": "FHIR Value set/code system definition for HL7 v2 table 0477 ( Controlled Substance Schedule)",
  "codeSystem": {
    "extension": [
      {
        "url": "http://hl7.org/fhir/StructureDefinition/valueset-oid",
        "valueUri": "urn:oid:2.16.840.1.133883.18.304"
      }
    ],
    "system": "http://hl7.org/fhir/v2/0477",
    "caseSensitive": false,
    "concept": [
      {
        "extension": [
          {
            "url": "http://hl7.org/fhir/StructureDefinition/valueset-comments",
            "valueString": "Includes drugs that have a high potential for abuse, no currently accepted medical use in the United States and a lack of accepted safety for use under medical supervision."
          }
        ],
        "code": "I",
        "display": "Schedule I"
      },
      {
        "extension": [
          {
            "url": "http://hl7.org/fhir/StructureDefinition/valueset-comments",
            "valueString": "Includes drugs having currently accepted medical use in the United States and a high abuse potential, with severe psychological or physical dependence liability."
          }
        ],
        "code": "II",
        "display": "Schedule II"
      },
      {
        "extension": [
          {
            "url": "http://hl7.org/fhir/StructureDefinition/valueset-comments",
            "valueString": "Includes drugs having an abuse potential less than that of drugs listed in Schedules I and II. All CS III drugs have a currently accepted medical use in the United States."
          }
        ],
        "code": "III",
        "display": "Schedule III"
      },
      {
        "extension": [
          {
            "url": "http://hl7.org/fhir/StructureDefinition/valueset-comments",
            "valueString": "Includes drugs having a lesser potential for abuse than those listed in Schedule III. CS IV drugs have a currently accepted medical use in the United States."
          }
        ],
        "code": "IV",
        "display": "Schedule IV"
      },
      {
        "extension": [
          {
            "url": "http://hl7.org/fhir/StructureDefinition/valueset-comments",
            "valueString": "Includes drugs having low abuse potential and limited physical or psychological dependence relative to those listed in IV and have an accepted medical use in the United States."
          }
        ],
        "code": "V",
        "display": "Schedule V"
      },
      {
        "extension": [
          {
            "url": "http://hl7.org/fhir/StructureDefinition/valueset-comments",
            "valueString": "State defined"
          }
        ],
        "code": "VI",
        "display": "Schedule VI"
      }
    ]
  }
}

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.